Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 704395, 8 pages
http://dx.doi.org/10.1155/2014/704395
Research Article

Isolated IgA Anti-β2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome

1Servicio de Inmunología, Instituto de Investigación Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
2Servicio de Nefrología, Instituto de Investigación Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
3Servicio de Reumatología, Instituto de Investigación Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
4Servicio de Hematología, Instituto de Investigación Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041 Madrid, Spain
5Sección de Inmunología, Universidad San Pablo-CEU, Campus de Monteprincipe, 28668 Madrid, Spain

Received 20 December 2013; Revised 3 February 2014; Accepted 17 February 2014; Published 23 March 2014

Academic Editor: Pier-Luigi Meroni

Copyright © 2014 Raquel Ruiz-García et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Seronegative antiphospholipid syndrome (SNAPS) is an autoimmune disease present in patients with clinical manifestations highly suggestive of Antiphospholipid Syndrome (APS) but with persistently negative consensus antiphospholipid antibodies (a-PL). IgA anti-β2 Glycoprotein I (aB2-GPI) antibodies are associated with APS. However, they are not currently considered to be laboratory criteria due to the heterogeneity of published works and the use of poor standardized diagnostic systems. We have aimed to assess aPL antibodies in a group of patients with clinical manifestations of APS (C-APS) to evaluate the importance of the presence of IgA aB2GPI antibodies in APS and its relation with other aPL antibodies. Only 14% of patients with C-APS were positive for any consensus antibody, whereas the presence of isolated IgA aB2GPI antibodies was found in 22% of C-APS patients. In patients with arterial thrombosis IgA aB2GPI, antibodies were the only aPL antibodies present. Serologic profile in primary APS (PAPS) is different from systemic autoimmune disorders associated APS (SAD-APS). IgA aB2GPI antibodies are more prevalent in PAPS and IgG aB2GPI antibodies are predominant in SAD-APS. The analysis of IgA aB2GPI antibodies in patients with clinical manifestations of PAPS might avoid underdiagnosed patients and provide a better diagnosis in patients with SAD-APS. Laboratory consensus criteria might consider including analysis of IgA aB2GPI for APS diagnosis.